Polaris Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Polaris Group sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Polaris Group: 13 sponsored US clinical trials, 1 recruiting.
Polaris Group sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Pancreatic Cancer, with 1 trials.
Top-decile sponsor footprint
Polaris Group ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
NCT05001828
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
NCT02709512
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
NCT01910012
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
NCT02101580
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
NCT02101593
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
NCT02102022
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
NCT02029690
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
NCT01948843
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
NCT01665183
Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient
NCT01528384
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
NCT01497925
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
NCT01287585
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Polaris Group pipeline
1 recruiting of 13 indexed (8% open); 9 completed (69%).
Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Advanced Pancreatic Cancer (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Polaris Group: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Polaris Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
Related
What to do with this Polaris Group page
13 registered trials is a research-attention snapshot, not an endorsement of Polaris Group or any single study.
- 1 of Polaris Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Pancreatic Cancer is the condition Polaris Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Polaris Group pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.